TREA

79345734 - C CENYX BIOTECH

Follow

Information

  • Trademark
  • 79345734
  • Serial Number
    79345734
  • Registration Number
    7333762
  • Filing Date
    April 29, 2022
    2 years ago
  • Registration Date
    March 26, 2024
    10 months ago
  • Transaction Date
    November 23, 2024
    2 months ago
  • Status Date
    March 26, 2024
    10 months ago
  • Published for Opposition Date
    January 09, 2024
    a year ago
  • Location Date
    March 26, 2024
    10 months ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    SIMCOX,KYLE DUNCAN
  • Attorney Docket Number
    S26735
    Attorney Name
    Leigh Ann Lindquist
    Law Office Assigned Location Code
    N40
  • Owners
Information
Mark Drawing Code
5
Mark Identification
C CENYX BIOTECH
Case File Statements
  • DM0000: The mark consists of the following: a stylized letter "C" in the colors purple, green, blue-green, and teal. The wording "CENYX" appears in navy blue stylized font, and further below is the wording "BIOTECH" in blue-green stylized font.
  • CD0000: The color purple, blue-green, teal, emerald and navy are harmonized in C-shaped letter. The color navy appears in the word CENYX and the color blue-green appears in the word BIOTECH.
  • GS0051: Diagnostic reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; veterinary preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for animal and poultry; radio-isotope markers for therapeutic or diagnostic use; in vitro diagnostic preparations for medical purposes; vaccines; contrast media for use in medical imaging equipment; contrast media for in vivo imaging; drug delivery agents in the form of compounds, wrapping wafers, edible wafers that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the prevention of inflammatory disorders; non-prescription medicines, namely, medicinal preparations in the nature of pills, tablets, capsules, caplets, liquid drops, sachets, oral liquids, suspensions, liquids, semi-solids, creams, syrups, ointments, lotions, gels, sprays, emulations, oils, pessaries, suppositories, granules and films for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; radioactive pharmaceutical preparations for use in vivo diagnostics or therapeutic use; diagnostic agents for medical purposes; biological preparations for medical purposes, namely, biological preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for medical or veterinary purposes; pharmaceuticals for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the treatment of cardiovascular disease; drug delivery agents in the form of tablets or capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of inflammatory diseases; antibodies for medical purposes
  • CC0000: The color(s) purple, blue-green, teal, green, and navy blue is/are claimed as a feature of the mark.
  • DS0000: "BIOTECH"
  • GS0421: Scientific research in the nature of conducting clinical trials for others in the field of cardiovascular disease; scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research and development; Scientific research in the nature of conducting clinical trials for others in the field of medicine; analysis, and evaluation of medical product development services of others to assure compliance with industry standards; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy
Case File Event Statements
  • 7/22/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 7/21/2022 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 7/26/2022 - 2 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 2/17/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/8/2023 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 3/9/2023 - a year ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 4/27/2023 - a year ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 4/27/2023 - a year ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 5/17/2023 - a year ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 10/24/2023 - a year ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/24/2023 - a year ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 10/24/2023 - a year ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/5/2023 - a year ago
    13 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/7/2023 - a year ago
    14 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/29/2023 - a year ago
    15 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 11/29/2023 - a year ago
    16 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 11/29/2023 - a year ago
    17 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 11/29/2023 - a year ago
    18 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 11/29/2023 - a year ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 12/20/2023 - a year ago
    22 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 12/20/2023 - a year ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 12/27/2023 - a year ago
    24 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 12/27/2023 - a year ago
    23 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 1/9/2024 - a year ago
    26 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/9/2024 - a year ago
    27 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/26/2024 - 10 months ago
    29 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 3/26/2024 - 10 months ago
    30 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 6/27/2024 - 7 months ago
    31 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 10/7/2024 - 4 months ago
    33 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 10/7/2024 - 4 months ago
    32 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 12/20/2023 - a year ago
    21 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 1/8/2024 - a year ago
    25 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 1/13/2024 - a year ago
    28 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 11/23/2024 - 2 months ago
    34 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO